BIO-PATH HOLDINGS INC

BPTH NASDAQ

AlenCiken

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology Provides Expanded Protection to Seminal Patents Related to DNAbilize The new patent builds on earlier patents granted that protect the platform technology for DNAbilize®, the Company’s novel RNAi nanoparticle...

dobisa

Looks good to me

OrdinariusTrader

Hi. Look at this beauty. If you want new shares, like wildly and follow wildly. It is my personal opinion. It isn't investment advice.

UnderwearTrader

Is it time for this beast to reawaken? May 29th we will find out!

TheAmericanTaxpayer

Daily looks like bearflag, expect strong move soon to 5.3ish where i will be adding.

RayleWoodInvestments

BPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact...

mauretto432

BPTH = LONG FLAG ALLERT AS CATALIST EARNING ..PAY ATTENTION from 9$ TP1 18$ TP2 28$ TP 3 35 $ STAY TUNED 95 % RETURN

TopMarketGainers

ANALYSTS UPGRADE WITH $28 TAGRGET H.C. Wainwright analyst Yi Chen started Bio-Path Holdings with a Buy rating and $28 price target. The company possesses an "intriguing" technology platform, DNAbilize, consisting of a novel and proprietary way to achieve sustainable systemic delivery of antisense oligonucleotides, Chen tells investors in a research note. Further,...

dmjs12

Getting ready.

dmjs12

200d determines all. nice move but will it follow thru?

Skinwah

MMHVW - let’s see is a ab=cd plays out.

TopMarketGainers

Stock picking has no certainties and often the greatest signals are from whispers among the investment community. Bi-Path Holdings has had quite a lot of good news recently that has brought it to the attention of many investors. Despite this we think that the price is gearing up for a significant move upwards, so we have alerts set on price and RSI spikes. This is...

SwingBatter12

Going for 30 high risk as moved alot

StockGuild

Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...

doebop97

What the fuck do they have? Cure for AML? other L, other Cancer? i dont' know but it's too cheap here!!

erindollar23

This stock BPTH has HIGH volume with breaking previous day highs also with the recent pullback TOP green candle. Looking for a interesting LONG.

licagavrila

BPTH 120

kumori1030

Horrible long term chart